Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 03 2021 - 7:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its
charter)
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
ADC Therapeutics
Announces Medical Leadership Transition
ADC Therapeutics SA (the “Company”)
announced that, effective September 3, 2021, Jay Feingold, the Company’s current Senior Vice President and Chief Medical Officer,
will depart the Company to pursue a new opportunity. In addition, effective September 4, 2021, Joseph Camardo, MD, the Company’s
current Vice President of Medical Affairs, is appointed as the Company’s Senior Vice President and Chief Medical Officer. Dr. Feingold
will continue to consult with the Company through 2022 to ensure a smooth transition.
Below are Dr. Camardo’s biography
and other information required by Item 6.A. of Form 20-F:
Joseph Camardo, MD, age 68, was appointed
as our Senior Vice President and Chief Medical Officer on September 4, 2021. From January 2020 to September 2021, Dr. Camardo served
as our Vice President of Medical Affairs. From 2010 to 2020, Dr. Camardo held various senior positions at Celgene Corporation, including
as Senior Vice President of Celgene Global Health and Senior Vice President of Global Medical Affairs and Corporate Medical Operations.
Prior to that, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and held
several leadership positions at Wyeth Pharmaceuticals, Inc., including as Senior Vice President of Clinical Research and Development.
There are no family relationships between
Dr. Camardo or any of our directors or other executive officers.
INCORPORATION
BY REFERENCE
This Report on Form
6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-256686 and 333-256807)
of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents
or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
ADC Therapeutics SA
|
Date: September 3, 2021
|
|
|
|
|
By:
|
/s/ Michael Forer
|
|
Name:
|
Michael Forer
|
|
Title:
|
Executive Vice President and General Counsel
|
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024